Literature DB >> 23294123

Recent advances of natural orifice transluminal endoscopic surgery in urological surgery.

Laura Izquierdo1, Lluis Peri, Eduardo García-Cruz, Mireia Musquera, Marta Piqueras, David Gosálbez, Antonio Alcaraz.   

Abstract

Natural orifice transluminal endoscopic surgery designates a surgical procedure that utilizes one or more patent natural orifices of the body with the intention to puncture a hollow viscera in order to enter the abdominal cavity. First carried out at the beginning of the 2000s in experimental models, it can be considered the natural evolution of laparoscopy towards the ideal of scarless surgery, as the avoidance of a large abdominal scar is associated with better cosmetic results and better recovery. However, the technology currently available does not allow the performance of complete pure natural orifice transluminal endoscopic surgery procedures. The surgical tools used are not specially designed for this approach, so difficulties in retracting organs, bleeding control and clashing of instruments are the main obstacle surgeons face. For this reason, the current available technique is the so-called hybrid approach, where a natural orifice approach is combined with some abdominal trocars, using the natural orifice as the exit door for the specimen removal. As not many comparative studies have been published evaluating the advantages of natural orifice transluminal endoscopic surgery in front of traditional laparoscopic surgery, a review of the history of natural orifice transluminal endoscopic surgery, and an assessment of the available evidence of this technique regarding renal and urological pelvic surgery are performed in this article.
© 2013 The Japanese Urological Association.

Mesh:

Year:  2013        PMID: 23294123     DOI: 10.1111/iju.12066

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  1 in total

Review 1.  Advances in laparoscopic surgery in urology.

Authors:  Jens J Rassweiler; Dogu Teber
Journal:  Nat Rev Urol       Date:  2016-05-24       Impact factor: 14.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.